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Abstract: The function of proteasomes in extracellular space is still largely unknown. The extracellular
proteasome-osteopontin circuit has recently been hypothesized to be part of the inflammatory
machinery regulating relapse/remission phase alternation in multiple sclerosis. However, it is
still unclear what dynamics there are between the different elements of the circuit, what the role of
proteasome isoforms is, and whether these inflammatory circuit dynamics are associated with the
clinical severity of multiple sclerosis. To shed light on these aspects of this novel inflammatory circuit,
we integrated in vitro proteasome isoform data, cell chemotaxis cell culture data, and clinical data of
multiple sclerosis cohorts in a coherent computational inference framework. Thereby, we modeled
extracellular osteopontin-proteasome circuit dynamics during relapse/remission alternation in
multiple sclerosis. Applying this computational framework to a longitudinal study on single multiple
sclerosis patients suggests a complex interaction between extracellular proteasome isoforms and
osteopontin with potential clinical implications.
Keywords: immunoproteasome; chemotaxis; computational modelling; system biology
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1. Introduction
Multiple sclerosis (MS) is a chronic disease of the central nervous system characterized by the
presence of inflammation, myelin damage, and axonal degeneration. The causes of MS remain
elusive; however, several studies suggest an immune pathogenesis involving a predisposing genetic
background in combination with environmental and immune factors [1,2].
Osteopontin (OPN) is not only a component of the bone matrix but also a soluble pleiotropic
cytokine. It has been theorized that OPN is a key inflammatory molecule in MS and in other diseases,
which is supported by numerous studies [1]. Indeed, OPN concentration increases in bodily fluids
during the relapse phase in patients affected by relapsing-remitting multiple sclerosis (RRMS). OPN
is abundantly secreted in MS lesions. Further evidence has been provided by studies carried out in
experimental autoimmune encephalomyelitis (EAE) mice, which is the main mouse model of MS.
In this model, OPN administration results in rapid relapse induction, increased neurological defect
levels, and disease progression [3,4].
The secreted form of OPN can be processed by proteases such as matrix metalloproteinases and
thrombin [1]. In particular, thrombin cleaves the full length secreted OPN (OPN-FL) into N-terminal
(OPN-N) and C-terminal (OPN-C) portions, which exert different biological activities in comparison
to OPN-FL. Some of these functions are leucocyte chemotaxis and adhesion, as well as survival and
differentiation. It has been hypothesized that this gain of function upon processing could be due to
exposure of portions of the OPN protein that are not accessible in the OPN-FL form [1,5].
Another protease present in many types of biological fluid is the extracellular 20S proteasome,
although this multi-catalytic enzyme is widely studied in its role as an intracellular protease for which
it degrades the majority of intracellular proteins. There are different proteasome isoforms with varying
catalytic subunits assembled in their barrel-shaped structure. Standard proteasomes are comprised of
the β1, β2, and β5 subunits, whereas the immunoproteasome contains the β1i, β2i, and β5i subunits.
Immunoproteasomes are normally expressed in cells exposed to an inflammatory milieu or in specific
pathological environments, as well as being constitutively expressed in immune cells [6]. These two
proteasome isoforms differ in terms of structure, peptide-bond hydrolysis, peptide transport within the
proteasome chamber, and transport regulation [7,8]. This results in overall diverse proteolytic dynamics
and substrate-specific degradation rates [7,9–13], which are likely responsible for the preferential
involvement of the immunoproteasome, for instance, in the regulation of cytokine-mediated
inflammation and cell-mediated immunity [14,15]. Immunoproteasome concentration is increased in
various cells involved in neurological diseases with inflammatory components, such as Alzheimer’s
disease, Huntington’s disease, epilepsy, and MS [16–22]. Furthermore, immunoproteasomes worsen
the phenotype in EAE mice despite the biological mechanisms mediating these effects still being largely
unknown [23,24].
We recently speculated that the involvement of immunoproteasomes in EAE and MS could be
in part due to its regulation of OPN in the extracellular space [25]. What proteasomes do in the
extracellular space is still unclear, although we recently identified a reciprocal interaction between
extracellular proteasome and OPN, which leads to regulation of cell migration. Proteasome-catalyzed
degradation of OPN-FL and OPN-C generates specific peptide fragments present at the C-terminal
portion of the protein (from residues 217 to 306). These peptides enhance the migration of different
cell types involved in inflammation and angiogenesis, i.e., human umbilical vein endothelial cells
(HUVECs), peripheral blood lymphocytes (PBLs), and monocytes (PBMs). In contrast, proteasomal
proteolysis significantly hampers the chemotactic activity of OPN-N. In a sort of a feedback loop,
OPNs reduce the in vitro secretion of proteasomes by HUVECs but not by PBLs, thereby suggesting
cell-specific regulation of this process. This phenomenon seems to be confirmed in vivo in RRMS
patients’ sera. Indeed, in the sera of two independent Italian and German cohorts of RRMS patients in
relapse or in remission, we measured an increased concentration of OPN during the relapse phase,
which significantly correlated inversely with the levels of extracellular proteasomes. In these RRMS
cohorts, serum proteasome concentration is larger in patients in remission than in relapse or in
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comparison to healthy donors. Regarding the mechanism whereby OPNs reduce the secretion of
proteasomes in the extracellular space, we detected proteasomes in both extracellular vesicles and
vesicle-free supernatant in sera. The proteasome content that is influenced by the RRMS phase seems
to be the latter. This suggests a secretion mechanism alternative to extravesicles that has not yet been
identified [25].
To untangle the complex implications of the extracellular proteasome-OPN circuit in MS
relapse/remission alternation, a pure in vitro/ex vivo experimental strategy would be insufficient,
as it could limit the study to an observational level. In this study, we aim for a broader understanding
of this phenomenon and the implications that it may have in the clinical history of MS patients. This
can be achieved via mathematical modeling coupled to state-of-the-art statistical inference, as has been
done in the past to decipher proteasome dynamics [7,26–30].
2. Materials and Methods
2.1. In Vitro Processing of OPNs by Purified 20S Proteasomes
To begin, 20S proteasomes were purified from T2 and lymphoblastoid cell lines (LCLs), as well
as peripheral blood of an RRMS patient in relapse and an age- and gender-matched healthy control,
as previously described [31]. The purity of 20S proteasome preparation has been shown elsewhere [9].
LCLs are human B lymphocytes immortalized via Epstein Barr virus transformation that primarily
express immunoproteasomes [32]. We pooled LCLs from 5 donors carrying different β1i and β5i
subunit polymorphisms to minimize the bias on proteasome activity [19,32–34]. The T2 cell line is a
human T cell leukemia/B cell line lacking β1i and β5i subunits and thus expressing only standard
proteasomes [9].
Experiments were carried out using recombinant OPN-FL (OPN17-314-6His), OPN-N
(OPN17-168-6His), and OPN-C (OPN169-314-6His), which are here reported as OPNs. The amount
of 0.4 µg recombinant OPNs were incubated in kinetics experiments (0–4 h) at 37 ◦C with 3.5 µg
20S proteasomes purified from either T2 and LCLs (Figure 2A) or from the peripheral blood of an
RRMS patient and an age-matched healthy control (Figure S1) in 20 µL Roswell Park Memorial
Institute (RPMI) medium. The ratio of OPNs/proteasomes used in the kinetics assays mimicked that
observed in serum of healthy and MS donors [25]. OPNs’ degradation was detected and quantified by
immunoblotting as previously described [9].
2.2. Cell Culture
HUVECs were isolated from human umbilical veins and grown as previously described [25].
The use of primary human cells was approved by the Ethics Committee of the “Presidio Ospedaliero
Martini” of Torino and conducted in accordance with the Declaration of Helsinki. Written informed
consent was obtained from all donors.
2.3. Cell Migration Assay
Cell migration assays were carried out in the Boyden chamber (BD Biosciences) as previously
described [25]. Briefly, 2 × 103 HUVECs were plated onto the apical side of 50 µg/mL Matrigel-coated
filters in M200 serum-free medium. Ten µg/mL OPN-FL, OPN-C, or OPN-N were placed in the
basolateral chamber; 10 ng/mL VEGF-α were used as a reference chemoattractant. 20S proteasome
isoforms were pre-incubated with OPN-FL, OPN-C, and OPN-N—with ratio proteasome (ng):OPNs
(ng) = 20:1—for 2 h at 37 ◦C under 5% CO2 and subsequently placed in the basolateral chamber.
After 3 h, the cells on the bottom of the filter were stained with crystal violet and counted. Data are
shown as a percentage of treated cell migration versus the control migration measured for untreated
cells. Control migration was (mean± SD) 87± 7.9 for HUVECs (n = 17). The same assay and conditions
were used in the migration assays described by Dianzani et al. [25] (and used for developing the
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computational model) except the cell migration period (20 h instead of 3 h). Furthermore, in the study
of Dianzani et al. [25], the PBL migration assay was carried out using 5 × 104 PBLs.
2.4. Donor Enrolment and Sample Preparation
RRMS patients and age-, gender-, and ethnicity-matched healthy controls without a history of
any neurological or other chronic disease were recruited for the study of Dianzani et al. [25] and are
summarized in Table S3. The blood samples of the Italian donor cohort were obtained after informed
consent and ethical approval by the University of Piemonte Orientale (Novara; ethical committee
approval: CE 18/04) and the University of Milano (ethical committee approval: 2014/020). Diagnosis
of MS was made according to the McDonald 2010 criteria [35], and inclusion criteria are described
elsewhere [25]. For the longitudinal study, which was not included in the previous study [25], 10 mL
of peripheral blood was drawn, and the serum was separated at the time of relapse (2–7 days from its
onset) and of remission (after 0.5–8 months from the last relapse; the average period after the relapse
is 3 months). The RRMS patients received corticosteroid treatment right after the blood withdrawal
during the relapse. Blood of healthy donors was withdrawn at t0 (i.e., at the baseline, 0 months) and
1–5 times within 23 months.
All patients underwent clinical evaluations in relapse and remission, and the expanded disability
status scale (EDSS) [36] was filled in at each time-point. To take into consideration the effect of time on
disability accumulation, we calculated the multiple sclerosis severity score (MSSS) [37]. The MSSS was
based on databases from 11 countries, extracting disease duration (in years) and last EDSS assessment
of 9892 patients. The algorithm related a patient’s disability severity according to his/her EDSS to the
distribution of disability in others with the same disease duration. In this model, similar relatively
high MSSS numbers were assigned to patients who accrued moderate disability over a short period of
time or severe disability over a moderate period of time. MSSS was calculated as a decile of the EDSS
using the average of the lowest and highest ranks for each possible EDSS at a certain disease duration,
which was normalized by dividing by 1 plus the number of available assessments for that year and
then multiplied by 10.
To compute the ∆MSSS and the MSSS, we applied the following formulas: ∆MSSS =
−(MSSSremission − MSSSrelapse); MSSS’ = ∆MSSS × MSSSrelapse. The latter two variables better
represent the worsening of symptom severity in the transition from remission to relapse.
2.5. Extracellular Proteasome and OPN Quantification in Serum
The concentration of the extracellular proteasomes was measured in serum by ELISA,
as previously described [25]. All assays were performed in two biological units and measured in three
technical replicates.
2.6. Statistical Analysis and Data Availability
Data were tested for normality and homoscedasticity by the Shapiro-Wilk and
Kolmogorov-Smirnov tests, and the Levene test, respectively. To identify significant variation
in chemotaxis upon different stimuli, we applied the Wilcoxon test for paired samples. Pearson’s
correlation coefficients were computed for correlation analyses. A bootstrap test (1000 samples using
100% of the data) was performed to obtain confidence intervals for the correlation coefficient between
OPN and 1/extracellular proteasome, as previously described [25]. Descriptive statistics were carried
out with SPSS (version 17) and R; a p-value < 0.05 was considered statistically significant.
Data are available at Mendeley Data Archive: doi:10.17632/67x4cfgz7p.1.
2.7. Mathematical Modeling
The mathematical model consisted of a set of ordinary differential equations that described the
time course of extracellular proteasome (pi and ps for immuno- and standard- proteasomes), OPNs
(OPN-FL OPNF, OPN-N OPNN, and OPN-C OPNC), and the resulting OPN fragments (Fsf, Fsn, and Fsc
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for standard proteasome-generated fragments, Fif, Fin, and Fic for immunoproteasome-generated
fragments) upon proteasomal degradation. The model parameters were estimated, when possible,
from the experimental measurement of serum OPN and proteasome concentrations in RRMS,
healthy donors of the Italian cohort [25], and the in vitro degradation of OPNs by standard- and
immuno-proteasomes (Figure 2A–B).
The period of relapse in the MS patients was arbitrarily set to 4 weeks. The model was
implemented in R and numerically integrated using LSODA (R package deSolve) [38,39]. All further
model analysis was done in R using the packages plot3D [40] and code for parameter inference,
and model simulations can be obtained upon request. The details of the model derivation and
parameter estimation are as follows:
The Ordinary Differential Equation (ODE) system is defined as:
dpi
dt
= kin
Xi
1 + kiOPNtot
− pikdeg (1)
dps
dt
= kin
1− Xi
1 + kiOPNtot
− pskdeg (2)
dOPNF
dt
= γk1 −OPNF
(
kcutF,i pi
KMF,i + OPNF
+
kcutF,s ps
KMF,s + OPNF
)
− kdegFOPNF (3)
dOPNN
dt
= γk1
1− Xt
Xt
−OPNN
(
kcutN,i pi
KMN,i + OPNN
+
kcutN,s ps
KMN,s + OPNN
)
− kdegNOPNN (4)
dOPNC
dt
= γk1
1− Xt
Xt
−OPNC
(
kcutC,i pi
KMC,i + OPNC
+
kcutC,s ps
KMC,s + OPNC
)
− kdegCOPNC (5)
dFi f
dt
= pi
kcutF,iOPNF
KMF,i + OPNF
− Fi f kdeg3 (6)
dFin
dt
= pi
kcutN,iOPNN
KMN,i + OPNN
− Finkdeg3 (7)
dFic
dt
= pi
kcutC,iOPNC
KMC,i + OPNC
− Fickdeg3 (8)
dFs f
dt
= ps
kcutF,sOPNF
KMF,s + OPNF
− Fs f kdeg3 (9)
dFsn
dt
= ps
kcutN,sOPNN
KMN,s + OPNN
− Fsnkdeg3 (10)
dFsc
dt
= ps
kcutC,sOPNC
KMC,s + OPNC
− Fsckdeg3 (11)
where ps and pi are extracellular standard- and immuno-proteasomes, respectively, OPNtot is the total
concentration of OPN-FL, OPN-N, and OPN-C, OPNF is OPN-FL, OPNN is OPN-N, OPNC is OPN-C, Xt
is the fraction of OPN-FL relative to OPN-C and OPN-N, and Xi is the fraction of immunoproteasomes
relative to standard proteasomes. OPN-derived fragments generated by immunoproteasome are
denoted Fif, Fin, and Fic for the fragments of OPN-FL, OPN-N, and OPN-C, respectively. OPN-derived
fragments generated by standard proteasomes are denoted Fsf, Fsn, and Fsc for the fragments of OPN-FL,
OPN-N, and OPN-C, respectively (see also Table S2). The model parameters kin, ki, kdeg, k1, kdeg2, kdeg3,
KMF,i, KMN,i, KMC,i, KMF,s, KMN,s, KMC,s, kcutF,i, kcutN,i, kcutC,i, kcutF,s, kcutN,s, kcutC,s, and kdeg3 are
defined in Table S3. The initial conditions for pi, ps, OPNF, OPNN, and OPNC were sampled from the
experimental data of Italian RRMS patients in remission [25]. The parameters were inferred from the
experimental data [25]. Here, we used three types of data to inform different parameters: (i) remission
and relapse measurements of osteopontin and extracellular proteasomes in serum of RRMS patients,
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(ii) in vitro degradation kinetics of OPNs with purified standard- and immuno-proteasomes, and (iii)
chemotaxis assays monitoring migration of HUVECs, lymphocytes, and monocytes in response to
unprocessed as well as proteasome-processed OPNs. In particular:
(i) RRMS patient data to estimate transport parameters:
We first focused on determining kin and kdeg, which describe the rate of proteasome release into
the extracellular space and the degradation of extracellular proteasomes, respectively. Both parameters
were unknown, but we assumed that during remission, the concentration of extracellular proteasome
was constant, i.e., in a steady state. We then had:
dp
dt = 0 (Equations (1)–(2)), which results in kin = premkdeg(1 + kiOPNtot,rem), where prem is
the concentration of extracellular proteasomes during remission, and OPNtot,rem is the total OPN
concentration during remission.
We next determined ki (rate of proteasome release inhibition by OPNs). Using the steady state
experimental data during relapse and remission, respectively, we obtained (Equations (3)–(5)):
ki =
prel−prem
premOPNtot,rem−prelOPNtot,rel , where prel is the concentration of extracellular proteasomes during
relapse and OPNtot,rel is the total OPN concentration during relapse. Next, we determined the
parameters kdeg2 and k1, which describe OPN degradation and release into the extracellular space,
respectively. In steady state during remission, we had: dOPNF,remdt = 0,
dOPNN,rem
dt = 0 and
dOPNC,rem
dt = 0,
which resulted in (Equations (3)–(5)):
kdegF =
k1
OPNF,rem
−
(
kcutF,i
KMF,i + OPNF,rem
+
kcutF,s
KMF,s + OPNF,rem
)
, (12)
kdegN =
k1
OPNN,rem
−
(
kcutN,i
KMN,i + OPNN,rem
+
kcutN,s
KMN,s + OPNN,rem
)
and (13)
kdegC =
k1
OPNC,rem
−
(
kcutC,i
KMC,i + OPNC,rem
+
kcutC,s
KMC,s + OPNC,rem
)
. (14)
During relapse, k1 is increased by a factor γ, which, based on the experimental data,
can be computed as γ = prelOPNF,relk1
{(
kcutF,i
KMF,i+OPNF,rel
− kcutF,sKMF,s+OPNF,rel
)
Xi +
kdegF
prel
}
. To determine the
parameters, we drew 1000 samples of OPN and proteasome measurement, obtaining parameter
distributions to account for uncertainty.
Thus far, we were able to determine the parameters kin, kdegF, kdegN, kdegC, ki, and γ, and only kdeg,
kdeg3 and k1 remained unknown.
(ii) In vitro OPN degradation kinetics:
In the following, we inferred the parameters related to OPN degradation by standard proteasomes
(KMF,s, KMN,s, KMC,s, kcutF,s, kcutN,s, kcutC,s) and by immunoproteasomes (KMF,i, KMN,i, KMC,i, kcutF,i,
kcutN,i, kcutC,i). Since patient-derived data describing OPN degradation by proteasomes in serum
could not be experimentally collected, we inferred the related parameters from in vitro digestions of
OPNs. The differential equations for the formation of OPN fragments (Fsf, Fsn, and Fsc for standard
proteasome, and Fif, Fin, and Fic for immunoproteasome) in vitro were:
dFs f
dt
= pskcutF,s
OPNF
KMF,s + OPNF
(15)
dFsn
dt
= pskcutN,s
OPNN
KMN,s + OPNN
(16)
dFsc
dt
= pskcutC,s
OPNC
KMC,s + OPNC
(17)
dFi f
dt
= pikcutF,i
OPNF
KMF,i + OPNF
(18)
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dFin
dt
= pikcutN,i
OPNN
KMN,i + OPNN
(19)
dFic
dt
= pikcutC,i
OPNC
KMC,i + OPNC
(20)
We used exact Bayesian inference (Metropolis Hastings algorithm implemented in R) to infer the
posterior parameter distributions based on the experimental data.
Finally, we obtained all the parameters required for the model simulations (setting kdeg = kdeg3 =
2 × 10−4 and k1 = 10−4).
(iii) Chemotaxis assays:
We aimed to compute the level of chemotaxis over the progress of the disease phases. We
computed the level of chemotaxis as the sum of all chemotactic substances in the system multiplied by
their chemotactic index, i.e.:
Ctot(t) = ciOPNFOPNF(t) + ciOPNNOPNN(t) + ciOPNCOPNC(t) + ciFs f Fs f (t)
+ciFsnFsn(t) + ciFscFsc(t) + ciFi f Fi f (t) + ciFinFin(t) + ciFicFic(t),
(21)
where ci are the chemotactic indices of OPNs and their respective fragments. The values of ci were
determined based on chemotactic experiments using a given cell type (HUVECs, lymphocytes,
and monocytes). In the experimental setup, the OPNs were incubated with either standard- or
immuno-proteasomes for 2 h. The reaction mix was then applied in a Boyden chamber experiment,
and migrating cells were counted over 20 h. The number of migrated cells relative to control is reported
as the overall relative chemotaxis (crsOPNF, crsOPNN, crsOPNC for standard proteasome treatment, and
criOPNF, criOPNN, criOPNC for immunoproteasome treatment). Since the chemotactic index describes the
relative chemotaxis per nM substance and per time, we solved the following equations for standard
proteasomes:
crsOPNF =
∫ 22
2
ciOPNFOPNFdt +
∫ 22
2
ciFs f Fs f dt, (22)
crsOPNN =
∫ 22
2
ciOPNNOPNNdt +
∫ 22
2
ciFsnFsndt, (23)
crsOPNC =
22∫
2
ciOPNCOPNCdt +
22∫
2
ciFscFscdt (24)
And for immunoproteasome
criOPNF =
∫ 22
2
ciOPNFOPNFdt +
∫ 22
2
ciFi f Fi f dt, (25)
criOPNN =
∫ 22
2
ciOPNNOPNNdt +
∫ 22
2
ciFinFindt, (26)
criOPNC =
22∫
2
ciOPNCOPNCdt +
22∫
2
ciFicFicdt (27)
In the absence of proteasomes, we obtained the chemotactic indices for OPNs (reported in
Table S2). By solving the equations for ciFOPNFL, ciFOPNN, and ciFOPNC as well as numeric integration,
we also obtained the remaining three indices. Numeric integration was done with sampled kinetic
parameters from the parameter posterior distributions obtained in (ii), which were needed to obtain
OPN and OPN-derived fragment concentration over time. This resulted in distributions for the
chemotactic indices.
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3. Results
3.1. Modeling the Extracellular Proteasome-OPN Circuit in MS
Based on the in vitro and ex vivo results previously obtained [25], we could sketch a preliminary
model of how the extracellular proteasome-OPN circuit could be involved in the phase alternation
in RRMS (Figure 1A). In particular, the release of proteasomes into the extracellular space during
traumatic injury or chronic pathological condition was already known [41]. This could explain why
the level of serum proteasomes in RRMS patients in remission is significantly higher compared to
healthy controls [25], possibly as a consequence of tissue dysfunction and distress. The development
of the first relapse in RRMS patients occurs together with (or is caused by) an increase of serum OPN.
The high extracellular proteasome content in the patient serum results in enhanced pro-inflammatory
stimulation due to enhanced proteasome-mediated OPN processing. It is important to note that 20S
proteasomes purified from the peripheral blood of either RRMS patients in relapse or healthy controls
degrade all three OPNs in vitro (Figure S1). The pro-inflammatory synergistic effect of extracellular
OPNs and proteasomes is rapidly hampered by OPN-mediated inhibition of proteasome release
by endothelial (and maybe other) cells in the extracellular space. This is supported by in vitro/ex
vivo results showing that OPNs reduce the amount of extracellular proteasomes in HUVEC cell
culture, and that there is lower serum proteasome concentration measured in RRMS patients in relapse
compared to their remission phase [25]. It is important to note that in the studied RRMS cohort,
the blood was withdrawn 2–7 days from the relapse onset. Thus, the hypothetical OPN-mediated
inhibition of proteasome release had time to show its effects.
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the mathematical model: intracellular proteasomes are released by endothelial cells and other cell types
(not identified) into the extracellular space (kin), where they can be degraded (kdeg). This physiological
phenomenon could be enhanced in relapsing-remitting multiple sclerosis (RRMS) and other chronic
diseases or upon traumatic injury, thereby leading to a chronically larger amount of proteasomes in
the extracellular space. The release of proteasomes by endothelial cells is inhibited by OPNs (ki) and
possibly other unknown factors, whereas other cells are insensitive to OPN-mediated inhibition of
proteasome release. ki is prominent during the RRMS relapse when OPN levels are higher, leading to a
decrease of proteasome release in the extracellular space. The pathological levels of extracellular
proteasomes are restored in the remission when the OPN concentration is diminished. In the
extracellular space, full length secreted OPN (OPN-FL) can be fragmented in OPN-C-terminal (OPN-C)
and OPN-N-terminal (OPN-N) by thrombin or processed by other proteases. Extracellular proteasomes
can cleave OPN-N (kdeg3), thereby partially compromising its chemotactic activity. The peptide
fragments generated by proteasomes via processing OPN-FL and OPN-C (kdeg3) have an enhanced
chemotactic activity compared to the parental proteins, thereby promoting the chemotaxis of different
cell types such as endothelial cells, lymphocytes, and monocytes [25]. (B) The simulation of OPN-FL
and extracellular (standard) proteasome concentrations over time for RRMS patients. The time window
is arbitrarily set. The behavior of OPN-FL during relapse is given, and the behavior of extracellular
standard proteasomes is a result of the modeled system. Here, we assume that only OPN-FL is present
in the extracellular space. The secretion of OPN-FL from cells in the extracellular (kin2) increases during
(or right before) the relapse in serum of RRMS patients by a γ factor. kin2 decreases at the end of
the relapse.
When negative feedback of OPN was less effective because of the decrease of extracellular OPN
concentration, extracellular proteasome levels started to rise up again to a (pathologically) steady
state in the remission phase. The mechanism mediating the inhibition of proteasome release in the
extracellular space by OPN is still unclear. We identified proteasomes in various extracellular vesicles,
although we hypothesized that other (unknown) mechanisms of release may have been involved in
the scenario observed in MS patients [25].
3.2. Development of a Mathematical Model Describing the Extracellular Proteasome—OPN Circuit during the
Recurrence of MS Remission and Relapse Phases
To understand how differing proteolytic preferences of proteasome isoforms can impinge on
extracellular proteasome-OPN circuit function in inflammation in the alternation of remission and
relapse in RRMS patients, it is mandatory to adopt a computational biology approach. Computational
modeling of proteasome dynamics has been successfully applied in the past [7,42].
In general, a computational model allows us to test our mechanistic understanding of a biological
system through the comparison of model simulations with experimental measurements obtained from
the system of interest. However, experimental measurements can only probe a limited number of
observables under defined experimental conditions. A computational model allows us to investigate
such processes that are hard or impossible to directly measure through experimentation. This is of
particular interest when modeling clinical data to describe disease progression in humans, as it
is the case for RRMS. Our mechanistic understanding lacks detailed time resolved data of the
molecular processes involved in RRMS. The development of novel model and parameter inference
approaches describing the information content in experimental data [43,44] provides us with the tools
to systematically integrate different data modalities. This allows us to obtain a better mechanistic
understanding of the dynamics of the molecular processes during the remission-relapse alteration.
Our in vitro and ex vivo data—presented here and in the previous study [25]—can be summarized
conveniently and concisely in a mathematical model that captures the different aspects of the
extracellular proteasome-OPN circuit. This model describes the dynamics of extracellular proteasomes,
OPN, and proteasome-generated OPN fragments in the context of MS. Proteasomes are released
from the cells into the blood and degraded at constant rates, kin and kdeg. The release of extracellular
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proteasomes is inhibited by OPN (ki), which itself is produced and degraded with rates (kin2 and kdeg2).
In our modeling scheme, OPN can exist in three forms: OPN-FL, OPN-N, and OPN-C. The different
OPNs can additionally be degraded by extracellular proteasomes, resulting in the production of OPN
fragments (FOPNFL, FOPNN, FOPNC), which can be further processed and degraded by other peptidases
(kdeg3) (Figure 1A; more details are available in the Material and Methods, Table S1, S2).
We first used the model to simulate the time course of extracellular OPNs and proteasomes
in RRMS patients (Figure 1B). The initial conditions as well as parameter values were estimated
from experimental data obtained from sera of the Italian cohort of healthy donors, RRMS patients
in remission, and RRMS patients in relapse [25]. Healthy donors have a lower serum proteasome
concentration compared to RRMS patients in remission.
Furthermore, we computed the rate by which OPN inhibited the proteasome release from the
difference in extracellular proteasome concentration between relapse and remission in RRMS patients,
considering that all three OPN forms had the same potential for inhibition, as previously shown [25].
In our first analysis, we assumed that only OPN-FL was present in blood. We later considered other
scenarios because our ex vivo assay could only detect OPN-FL. In healthy donors, the concentration
of serum OPNs and proteasomes was lower than that in RRMS patients and was constant over time
(data not shown), which led us to assume that they were also constant in RRMS patients during
remission. During the onset of the relapse, more OPN was produced (kin2 increased) for two (arbitrary)
weeks and remained on its increased level for other two (arbitrary) weeks. After that, the rate of OPN
production was set back to its “normal” rate (kin2), resulting in a decreased serum OPN concentration,
i.e., back to its remission level. The factor γ by which kin2 increased during relapse was estimated
based on extracellular proteasome and OPN levels in RRMS patients during relapse (see Materials and
Methods for details).
Thereby, based on the OPN time course, we computed the dynamics of extracellular proteasomes
(Figure 1B).
3.3. Extracellular 20S Immunoproteasomes Process OPN Molecules Faster and Enhance Their
Chemotactic Activity
We initially mentioned existing indirect evidence that hints towards a preferential involvement
of immunoproteasomes in MS pathology. To test whether this could be in part due to differential
processing of secreted OPNs by immunoproteasomes (as compared to standard proteasomes) in
the extracellular space, we measured the in vitro degradation rate of human OPNs carried out by
purified standard- and immunoproteasomes. For this set of experiments, we used 20S standard-
and immuno-proteasomes. These are the proteasome isoforms that are most likely active in the
extracellular space, since they do not require the entire ubiquitin proteasome system to degrade
proteins. 20S proteasomes can only efficiently degrade partially disordered proteins because of
the reduced size of the proteasome gate [45]. This is the case for OPN, which we have previously
shown to be efficiently degraded in vitro by 20S proteasomes [25]. Correspondence between in vitro
experiments carried out with purified 20S proteasomes and in cellulo and in vivo experiments has
been demonstrated in various studies [12,13,46–57].
In our experimental set-up, all three OPNs were more rapidly degraded by immuno- rather
than standard-proteasomes (Figure 2A). We made use of the in vitro degradation kinetics to estimate
the proteasomal processing rates of OPN-FL, OPN-N, and OPN-C in a Bayesian inference scheme
(Figure 2B; see Materials and Methods). This allowed us to obtain posterior parameter distributions
(rather than point estimates) for OPN processing rates by standard- and immuno-proteasomes
(Figure 2C).
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Figure 2. Processing of OPNs by standard- and immu teasomes. (A) Representativ Western
Blot staining of the degradation kinetics of OPNs ( L, OPN-N, and OPN-C) by 20S standard-
and immuno-proteasomes (left panel; the proteasome α4 subunit is used as control marker);
the corresponding relative OPN’s degradation is also depicted (right panel; mean and SD of two
to three independent experiments measured in duplicate are shown). (B–C) Inference of kinetic
parameters determining the OPNs degradation dynamics by standard- and immuno-proteasomes.
Shown are the model fits based on simple Michaelis-Menten kinetics (B) and the inferred marginal
posterior parameter distributions for kcut (maximal reaction velocity) and KM (Michaelis-Menten
constant) using Bayesian inference via the Metropolis-Hastings algorithm (C).
The different degradation rates of OPNs between standard- and immuno-proteasomes could
have had a significant impact on the chemotaxis induced by OPN fragments. Therefore, we measured
the HUVECs’ migration upon stimulus with OPNs in the presence or absence of standard- or
immuno-proteas mes (Fig re 3A). HUVECs are a well-studied model to test chemotactic power
of different cytokines, including VEGF-α, which was used here as a positive chemotactic stimulus.
In agreement with the in vitro digestion results, when OPN-FL or OPN-C were processed by
immunoproteasomes, we observed a significant increase in chemotaxis in comparison to either
the unprocessed OPN-FL and OPN-C or the OPN fragments processed by standard proteasomes.
In contrast, the chemotactic activity of OPN-N was similarly hampered upon processing by either
standard- or immuno-proteasomes (Figure 3B).
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Figure 3. Extracellular im unoproteaso es e hance human umbilical vei endothelial cells
(HUVEC) migration more than standard proteasomes through the processing of OPN-FL and
OPN-C. (A) Images of migrated HUVECs (stained by crystal violet) treated with OPN-FL ± 20S
standard- or immuno-proteasomes in a representative Boyden chamber migration assay of 8–17
independent experiments. (B) Effect of OPNs (OPN-FL, OPN-N, and OPN-C) ± 20S standard-
or immuno-proteasomes, and VEGF-α as positive control, on the HUVEC chemotaxis. Values
are the percentage of treated versus untreated cells that migrated after 3 h and are the mean
and SD of independent experiments (n = 8–17). Wilcoxon tests for paired samples p < 0.05 are
shown. (C) Chemotactic indices for OPNs and their d rived fragments g erated by standard- and
immuno-proteasomes, respectively. Chemotactic indices are estimated from cell migration experiments
with HUVECs.
By computational deling, we computed that OPN fragments (FOPNFL, FOPNN, and FOPNC) and
OPNs had different chemotactic activities (Figure 3B), which we converted into a che otactic index
expressed as the chemotactic potential of a compound per mol and time (for details, see Methods
and Materials). The resulting chemotactic indices for unprocessed OPN-FL and OPN-C were smaller
than the chemotactic indices of their proteasome-generated fragments, while the chemotactic index
for unprocessed OPN-N was larger than the chemotactic index of its proteasome-derived fragments
(Figure 3C).
Furt ermore, immunoproteasomes generated OPN fragments with higher chemotactic index than
standard proteasomes (Figure 3C). This suggested a larger generation of chemotactic OPN fragments
by immunoproteasomes compared to standard proteasomes, as also indirectly supported by the
OPN-FL and OPN-C degradation rates (Figure 2A).
3.4. How the Balance between Proteasome Isoforms Can Impinge upon the Chemotaxis in RRMS Phases
We applied the computational model to describe the temporal dynamics of proteasome-generated
OPN fragments and the resulting level of chemotaxis in RRMS phases.
The related parameters were estimated from in vitro and cell culture experiments, as explained
above. Because we obtained posterior parameter distributions, we simulated the model 1000 times
with parameters sampled from these posterior distributions. We also sampled the initial conditions
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from the RRMS patient cohort data. This allowed us to estimate expected average behavior of the
system and uncertainty, which was propagated through the system, providing confidence ranges for
the simulation results.
By applying the computational model developed thus far, we could describe the variation of
serum OPN and proteasome concentration during the relapse and the remission before and after
the relapse in an archetypical RRMS patient. Because we showed that the OPN degradation rate
could depend on the proteasome isoform, in the model simulations, we distinguished between three
scenarios where (i) only standard proteasomes, (ii) only immunoproteasomes, and (iii) 50% standard-
and immuno-proteasomes were present in the serum (Figure 4A). Since OPNs were faster degraded by
immuno- rather than standard-proteasomes (Figure 2A), the model simulations suggested that more
OPN fragments would be generated if serum proteasomes were only immunoproteasomes (Figure 4B).
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Figure 4. Effect of proteasomes on chemotaxis duri S relapse and remission. All simulations
are done for standard proteasomes only (left column), im unoproteasomes only ( iddle colu n), and
50% standard- and immuno-proteasomes (right column). (A) Simulation of OPN-FL and extracellular
proteasome concentrations over time in MS patient serum. The behavior of OPN-FL concentration
during relapse is given, and the behavior of extracellular proteasome concentration is a result of the
modeled system. Here, we assume that only OPN-FL is present in the extracellular space. (B) Simulation
of the time course of proteasome-generated OPN fragments in MS patient serum. (C) Level of
chemotaxis over the course of the disease in MS patients. The chemotaxis is computed based on
the cell migration experiments performed wit HUVECs (Figure 3). Additionally, to the overall
expected che otaxis levels, the chemotaxis bas d only o OPN-FL, only on standard proteasomes, and
only on immunoproteasomes is shown, respectively.
Since the OPN fragments (FOPNFL, FOPNN, and FOPNC) and the OPNs had different chemotactic
activities, the overall chemotaxis was expected to be altered depending on the proportion of standard-
and immuno-proteasomes. We used the estimated chemotactic indices to simulate the chemotactic
activity over time during the remission and relapse of RRMS patients (Figure 3C).
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According to our model simulations, the chemotaxis promoted by OPNs quantitatively prevailed
over that promoted by OPN fragments (Figure 4C). The chemotaxis was, however, affected by the
proteasome isoform ratio. Immunoproteasomes triggered stronger OPN-mediated chemotaxis than
standard proteasomes, which benefited from a stronger impact of OPN-derived fragments on the
overall chemotaxis (Figure 4C).
3.5. How the Processing of OPN-FL by Thrombin Can Affect the Extracellular OPN-Proteasome Circuit
Although relevant to the inflammatory behavior, we did not have any information concerning
the OPN-FL/OPN-N/OPN-C ratio in the sera of healthy donors and MS patients. This ratio would
depend on a few proteases including proteasomes, since the latter degrades OPN-N and OPN-C with
different rates (Figure 2A). Therefore, we computed the chemotaxis for various concentrations of
OPNs and proportions of standard- versus immuno-proteasomes. In particular, we simulated the
increase in chemotaxis from the remission to the relapse in the archetypal RRMS patient to describe
how the variation of the ratios of OPNs and proteasome isoforms in blood could impinge upon the
cell migration dynamics of the relapse onset (Figure 5). The model simulations suggested that the
higher the thrombin activity in blood was (less OPN-FL and more OPN-N and OPN-C), the larger the
difference in chemotaxis between relapse and remission was (Figure 5A).
Furthermore, the more prevalent immunoproteasomes are in the blood (compared to standard
proteasome), the higher the chemotaxis difference between relapse and remission is (Figure 5B).
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Figure 5. Effect of proteasome isoforms and thrombin on chemotaxis in RRMS patients. (A) Overall
expected intensification in chemotaxis from RRMS remission to relapse dependant on the ratio
of standard- and immuno-proteasomes, as well as on the ratio of OPN-FL compared to OPN-N
and OPN-C. (B) Expected increase in chemotaxis from RRMS remission to relapse based only on
proteasome-generated OPN fragments. (C) Relative contribution of proteasome isoforms to the overall
expected level of chemotaxis.
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Our model simulations also suggested that extracellular proteasomes had the strongest effect on
chemotaxis when less thrombin was present in the blood (Figure 5C). This latter outcome indicated
that, in the absence of thrombin, the balance of proteasome isoforms could significantly alter the level
of cell chemotaxis and therefore the regulation of the inflammatory response in RRMS.
3.6. Extension of the Model to Immune Cells Infiltrating the Central Nervous System (CNS) of MS Patients
HUVECs are an established model for cell migration. However, in the pathophysiology of MS, the
cells that infiltrate the central nervous system (CNS) and are involved in brain damage are immune cells.
Among them, lymphocytes and monocytes are the most studied. They cross the blood-brain-barrier,
also attracted by OPN, and in the CNS, they promote inflammation and damage of the parenchyma [1].
We therefore verified whether these cells showed altered chemotactic behavior in response to OPNs
and proteasomes, and what could happen in the RRMS alternation phase. We repeated these analyses
by studying the migratory behavior of lymphocytes and monocytes and subsequently estimating their
chemotactic indices (Figure 6A). The model simulations were generated based on the lymphocyte and
monocyte migration ex vivo assays performed with OPNs and standard proteasomes [25]. Overall,
we found that the migration behavior in response to OPNs of lymphocytes and monocytes was
comparable to that of HUVECs, although monocytes showed higher levels of chemotaxis in the
absence of thrombin (Figure 6B) due to higher chemotactic indices resulting from OPN-Fl (Figure 6A).
This consistency between HUVECs and immune cells hinted toward a similar impact of standard- and
immune-proteasomes on the extracellular proteasome-OPN circuit. Therefore, we could preliminarily
extend the outcomes of the mathematical modeling of the cell migration in the presence of standard-
and immune-proteasomes—which were based on in vitro results obtained with HUVECs—to the
immune cells infiltrating the MS brain.
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Figure 6. Extracellular P and proteaso e dyna ics and related chemotaxis for HUVECs,
lymphocytes, and onocytes. ( ) he otactic indices of OPNs (OPN-FL, OPN-N, and OPN-C)
as well as their derived fragments generated by standard proteasomes for HUVECs, lymphocytes,
and monocytes. (B) Chemotaxis levels over the course of the disease for S patients based on cell
migration experiments [25] performed with HUVECs (left), lymphocytes (middle), or monocytes (right).
Simulations are based assuming that only standard proteasomes (absence of immunoproteasome) and
only OPN-FL (absence of thrombin) are present in the system.
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3.7. How the Extracellular OPN-Proteasome Circuit Could Impinge upon the Severity of the Relapse in
RRMS Patients
The proposed model of the extracellular proteasome-OPN circuit in MS (Figure 1A) was based
on the correlation of serum OPNs and proteasomes measured in Italian cohorts of RRMS patients,
whose blood was withdrawn either in the relapse or in the remission phase [25]. The fact that the
samples from the relapse and remission phases were not from the same patient could have caused bias.
Therefore, we measured the concentrations of OPNs and proteasomes in the sera of a new Italian cohort
of RRMS patients (n = 21), which was withdrawn during the relapse and different remission periods
(Table S3). The sera during the relapse was collected before steroid treatment to avoid interference by
the anti-inflammatory drug on our measurements; between one and four samples from each patient
were collected during the remission phase (i.e., 1–8 months after the relapse; average period of three
months). Five RRMS patients were excluded from the final analysis because of an incomplete set
of values.
In the remaining 16 RRMS patients, the serum proteasome concentration was significantly larger
in remission than relapse phase in a paired-sample analysis (Figure 7A), agreeing with our previous
study [25]. Furthermore, this allowed for confirmation of the (non-linear) inverse correlation between
serum OPN and proteasome levels (Figure 7B).
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patient follow-up cohort. (A) Variation of proteasome concentration between relapse and remission in
the sera of Italian RRMS patients (n = 16). In case of repeated withdrawals during the remission phase
(one to three withdrawals for each donor carried out between one and eight months), we calculated the
average serum proteasome and OPN levels of the repeated withdrawals and used it for the Wilcoxon
test for paired samples (p < 0.05 is shown). The means are depicted by a solid line. We obtained a
p = 0.010 when we excluded the two outliers with a relative proteasome concentration in remission
above 200% (n = 14). (B) Correlation between proteasome and OPN levels in sera withdrawn during
the relapse and remission phases (Pearson’s test, p < 0.001; C value is shown in the chart). We included
all measurements in the RRMS patients (n = 21) regardless of the MS phase. Therefore, for each
patient, one to five values are reported, which correspond to the number of serum samples in which
we successfully measured OPN and proteasome concentrations. A Bootstrap test using 90% of the data
showed a significant correlation coefficient between 0.3 and 0.8 (right panel). (C–E) Example model
simulation for a single RRMS patient [MS severity score (MSSS) = 23.8]. (C) Simulation of OPN-FL, total
OPNs, and extracellular proteasome concentrations over time for MS patients. For each single patient
simulation, we assumed a ratio of OPN-FL/(OPN-N + OPN-C) and standard-/immuno-proteasomes
equal to 0.5 in the extracellular space. (D) Time course of standard- and immuno-proteasome-generated
OPN fragments in the representative RRMS patient over time. (E) Level of chemotaxis over the course
of the disease in the representative RRMS patient. The chemotaxis was computed based on cell
migration experiments performed with HUVECs (Figure 3). In addition to the overall expected
chemotaxis levels, the chemotaxis based only on OPNs, only on standard proteasomes, and only on
immunoproteasomes is shown. (F–H) Performance evaluation of generalized linear models to detect a
relationship between the concentration of the extracellular OPN-proteasome circuit components (as
in Figure 1) and the relapse severity variables, expressed as MSSS (F), ∆MSSS (G), and MSSSS’ (H).
The model was generated using the six RRMS patients (group A) who had the expected variations
of serum OPNs and proteasomes from remission to relapse (black dots). The predicted and recorded
MSSS, ∆MSSS, and MSSSS’ of the further three RRMS patients (group B) who did not have the expected
variations of serum OPNs and proteasomes from remission to relapse are depicted in red dots (F–H
upper panels). In the lower panels of (F–H) are the coefficients of the generalized linear models to
detect relationships between the concentrations of extracellular OPN-proteasome circuit components
and MSSS (F), ∆MSSS (G), and MSSSS’ (H). Only significant components are shown.
One of the ultimate goals of this study was to verify whether there was a correlation between the
extracellular OPN-proteasome circuit and the RRMS patient’s disability. To do that, we considered
the EDSS of the RRMS patients enrolled in the prospective study. For nine out of 16 RRMS patients,
we could compute the MSSS, a quantitative measure of a patient’s disability corrected for disease
duration during relapse and remission, as well as the ∆MSSS and the MSSS’, which represent the MSSS
variation from remission to relapse.
In an initial analysis, no correlation between the MSSS, ∆MSSS, or MSSS’ and either the OPN or
proteasome concentration in serum was detected. Therefore, we applied our computational model to
simulate each patient separately and test whether the dynamics of each extracellular OPN-proteasome
circuit component might be correlated with the disability’s increase from remission to relapse. Since the
ratio of standard- versus immuno-proteasomes and between OPNs is not known, we simulated each
patient assuming 50% standard- and 50% immuno-proteasome, as well as 50% OPN-FL compared to
OPN-N and OPN-C. The simulation of the extracellular proteasome-OPN concentrations, the predicted
dynamics of proteasome-generated OPN fragments, and the resulting chemotaxis of a representative
patient are shown in Figure 7C–E. Among the nine patients, six showed the expected increase of
OPN and the expected decrease of proteasome concentrations from remission to relapse (group A),
whereas three patients showed diverging behavior (group B; see Figure 7F–H). After simulating each
patient based on their OPN and proteasome levels in remission and relapse, we tested whether the
model simulations in relapse and remission could be correlated with either the MSSS, ∆MSSS (data
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not shown), or MSSS’ (Figure S2) of each patient in group A. No correlation could be detected for the
single pathway components.
We then tested whether we could predict the MSSS, ∆MSSS, and MSSS’ of each patient based
on a combination of the model components by fitting a generalized linear model with 10-fold
cross-validation. To this end, we generated models of various complexity in terms of input variables,
ranging from including only OPNs during relapse and remission to including all model variables.
We evaluated model performance via computation of the R2 value. We found that a linear model
based on the concentration of OPNs, proteasomes, and proteasome-generated OPN fragments during
remission and relapse showed the best performance to predict MSSS, ∆MSSS, and MSSS’ (Figure 7F–H).
By including more model components such as chemotaxis levels or distinguishing between
standard- and immuno-proteasome levels, we did not observe any significant performance
improvement (data not shown). Linear models not considering proteasomes and proteasome-generated
OPN fragments had very poor model performances predicting MSSS, ∆MSSS, and MSSS’ (R2 = 0.09,
0.05, 0.14, respectively). Linear models not considering OPNs and the resulting chemotaxis of those
chemokines, i.e., including only proteasomes and proteasome-generated OPN fragments, had better
model performances predicting MSSS, ∆MSSS, and MSSS’ (R2 = 0.67, 0.66, 0.74, respectively).
This outcome indicated that the concentration of extracellular proteasomes, OPNs, and their
derived fragments impinged upon the worsening of symptoms during the relapse of RRMS patients in
group A. By applying the same linear model to simulations based on the three group B patients, we
observed a strong discrepancy between their predicted MSSS’ values and the measured MSSS, ∆MSSS,
and the MSSS’ (Figure 7F–H, red dots). This suggested that the linear model could only predict the
MSSS, ∆MSSS, and MSSS’ of RRMS patients who had a variation of serum OPN and proteasome
concentration from remission to relapse. This is represented in Figure 1B, i.e., an increase of OPNs and
a decrease of extracellular proteasomes from remission to relapse.
It is important to note that the absolute values of the estimated coefficients of the linear model
were highest for the OPN concentration, and all remission coefficients were positive, while all relapse
coefficients were negative, indicating the importance of the change between remission and relapse
(Figure 7F–H).
4. Discussion
Despite the extensive presence of proteasomes in extracellular space, its function there is far
from being completely understood. Recently, we showed that extracellular proteasomes can regulate
some aspects of the immune response by interacting with OPN [25]. Using computational modeling,
we better defined the interplay between serum OPNs and proteasomes in relapse/remission alternation
in RRMS patients and how this interaction could affect chemotaxis. By applying our model, we
simulated the correlation between the serum OPN-proteasome circuit and the severity of the relapse in
RRMS patients followed over time in a prospective study. These computational simulations depict
a complex picture in which the final effect of modulation on the extracellular OPN-proteasome
circuit depends on several variables. Only some of these variables were experimentally tested in
this study. In our opinion, the model could streamline its efficacy once some biological aspects
of the pathological mechanism are experimentally defined. In particular, the model was based
on the concentration of proteasomes and OPNs in serum. This bodily fluid may represent only
part of the concentration of OPNs and proteasomes—and thus the OPN-proteasome ratio—in the
extracellular space of the CNS focal lesions. We speculate that the extracellular OPN-proteasome
inflammatory circuit plays a significant role in the regulation of RRMS inflammation in the perivascular
cuffing, the cerebrospinal fluid (CSF), and the CNS, where the concentrations of the extracellular
OPN-proteasome circuit components have only been partially measured [1,58]. In these regions,
the extracellular OPN-proteasome circuit dynamics could be significantly different to what was
measured in the serum and could be simulated by our computational model. A second element
to bear in mind is that the model does not account for some other factors that can influence the
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extracellular OPN-proteasome circuit functionality, such as the presence of autoantibodies against
proteasomes and OPNs. They can affect the amount and activity of free OPNs and proteasomes
and have been correlated to MS and EAE dynamics [59–61]. Our ELISA detection method cannot
directly address this matter. These latter factors might play a role in the differences between the RRMS
patient groups A and B in our longitudinal study. A third variable to be evaluated is the OPNs’ and
proteasome isoforms’ ratios in the serum and CNS. Indeed, the computational model simulates the
impact that variations of the relative concentration of OPN-FL versus OPN-N as well as standard-
versus immuno-proteasomes can have on chemotaxis. However, the direct experimental measurement
of the concentration of these specific molecules in the serum and CNS focal lesions could improve
the computational model and its applications. It is important to note that we previously described an
increased expression of the immunoproteasome subunit β1i in MS plaques as compared to non-MS
specimens [19]. Those results were obtained using immunohistochemistry. They showed a clear
expression of the immunoproteasome subunit β1i in oligodendrocytes, macrophages, and microglial
cells in MS plaques. They also hinted towards a signal specific to the subunit β1i in the extracellular
space of MS plaques, which was not observed in non-MS specimens [19].
Only upon including these factors in the computational model could we simulate the actual effect
of a potential therapy inhibiting extracellular proteasome activity in RRMS patients.
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variable description 
ps Standard proteasome 
pi immunoproteasome 
OPNF OPN-FL 
OPNN OPN-N 
OPNC OPN-C 
Fsf OPN-FL-derived fragments produced by standard proteasome 
Fsn OPN-N-derived fragments produced by standard proteasome 
Fsc OPN-C-derived fragments produced by standard proteasome 
Fif OPN-FL-derived fragments produced by immunoproteasome 
Fin OPN-N-derived fragments produced by immunoproteasome 
Fic OPN-C-derived-derived fragments produced by immunoproteasome 
 
Table S1. Mathematical model variables. 
 
 
parameters description 
transport dynamics 
kin rate of proteasome release into blood vessel 
kdeg rate of proteasome degradation 
k1 rate of OPN release into blood vessel 
kdegF rate of OPN-FL degradation 
kdegN rate of OPN-N degradation 
kdegC rate of OPN-C degradation 
ki rate of inhibition of proteasome release by OPN 
Xt proportion of initial OPN-FL compared to OPN-N and OPN-C 
kdeg3 rate of degradation of OPNs-derived fragments 
proteasomal OPN degradation 
kcutF,s  kcutF,i vmax of OPN-FL degradation by standard- and immuno-proteasomes, respectively 
KcutN,s  kcutN,i vmax of OPN-N degradation by standard- and immuno-proteasomes, respectively 
KcutC,s  kcutC,i vmax of OPN-C degradation by standard- and immuno-proteasomes, respectively 
KMF,s  KMF,i 
Michaelis-Menten constant for OPN-FL degradation by standard- and immuno-
proteasomes, respectively 
KMN,s  KMN,i 
Michaelis-Menten constant for OPN-N degradation by standard- and immune-
proteasomes, respectively 
KMC,s  KMC,i 
Michaelis-Menten constant for OPN-C degradation by standard- and immuno-
proteasomes, respectively 
chemotaxis 
ciOPNF chemotactic index of OPNF 
ciOPNN chemotactic index of OPNN 
ciOPNC chemotactic index of OPNC 
ciFsf chemotactic index of Fsf 
ciFsn chemotactic index of Fsn 
ciFsc chemotactic index of Fsc 
ciFif chemotactic index of Fif 
ciFin chemotactic index of Fin 
ciFic chemotactic index of Fic 
 
Table S2. Mathematical model parameters. 
 
 
 Healthy Controls RRMS 
Age (y) 
Count (n) 
Gender (M/F) 
Disease onset (y) 
Disease duration (y) 
31.8±6.7 
12 
3/9 
 - 
- 
36.9±9.1 
21 
7/14 
30.3±8.7 
6.9±6.2 
 
Table S3. Characteristics of RRMS donors enrolled in the prospective study. RRMS patients and healthy 
donors enrolled in the study from whom we have successfully measured the concentration of proteasome and 
OPN in at least one serum sample.  
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Figure S1. Proteasomes derived from serum of either RRMS patient or healthy controls can degrade 
OPNs. Degradation kinetics of OPNs (OPN-FL, OPN-N and OPN-C) by 20S proteasomes purified from whole blood 
of either one RRMS patient or an age-matched healthy control are shown by representative Western Blot assay 
(upper panel; the proteasome a4 subunit is used as control marker). 
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Figure S2. The MSSS’ cannot be predicted based on single components of the extracellular OPN-
proteasome circuit. Simulated pathway components based on single patient data (the six patients of group A) 
in relapse (A) and remission (B) plotted against the patients’ MSSS’ values. MSSS’ is a marker of the relapse 
clinical intensity and is defined as the MSSS variation from remission to relapse multiplied by the MSSS in relapse 
(DMSSS*MSSSrelapse). No correlations between single components and MSSS’ have been detected. Pathway 
components are plotted as boxplots, indicating the median, 25% and 75% quantiles as the box, and the 5% and 
95% quantiles as dashed lines. 
